Skip to main content
SteadySharesSteadySharesSteadyStShares
The market
MarketsDiscover
Follow the money
Super InvestorsPolitician TradesCrypto Desk
Yours
My WealthNews
Settings Sign in
Pre-market
SteadySharesMarketsDiscoverSuper InvestorsMy WealthPoliticiansCryptoNews
DiscoverAYTU
HealthcareNCMUSD

Aytu BioPharma, Inc.

$00123456789.0012345678900123456789-2.3%
52w low $1.80$3.07 52w high
Market data · last updated 1d ago
Market data
Market cap
$23.58M
52w range
$1.80 - $3.07
Beta
0.27
Sector
Healthcare
Data quality
83/100
Valuation
Forward P/E
14.0x
Quality & efficiency
Moat score
38/100
Return on equity
-52.6%
Profit margin
-24.8%
Debt / equity
0.51
Growth & analysts
Revenue growth
+6.4%
Analyst target
$9.67
Target upside
+362.5%
Analysts
3
Run the 10-point checklist before you buy How these numbers are made

About Aytu BioPharma, Inc.

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT A central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 17 years of age; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 15 years of age. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.

Valuation

ValueGrowthProfitHealthIncome23QUALITY
Overall Rating
46
Moderate quality
Moderate quality

Derived from filed metrics · High confidence (83% of the inputs available)

Moat Score38
Fair value estimate
Not covered by our valuation model yet.

Moat, fair value and rating computed by our valuation engine (ported from the original Python model).

Fundamentals

Market Cap
$23.58M
P/E Ratio
N/A
Dividend Yield
0.00%
Revenue Growth
+6.4%
Profit Margin
-24.8%
ROE
-52.6%
Debt / Equity
0.51
Beta
0.27

Statistics

Similar Stocks · Healthcare

Latest News · AYTU